Cure My Disease

Don't miss your cure!

 Log in / Sign up

Can insulin rewire muscle genes? a deep dive into cellular response

NCT ID NCT07780513

Knowledge-focused Sponsor: The University of Texas Health Science Center at San Antonio Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now This study
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Aug 21, 2026 · Last updated Aug 25, 2026 · Updated 2 times

Summary

This study investigates how insulin influences gene activity in different types of muscle cells. Researchers will use a technique called a euglycemic-hyperinsulinemic clamp to control insulin levels, then take small muscle samples to analyze which genes turn on or off in response. The goal is to identify genetic variations that affect insulin sensitivity, which could help explain differences in diabetes risk.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
Insulin infusion during a euglycemic-hyperinsulinemic clamp procedure
What this could lead to
Could reveal why some people's muscles respond differently to insulin, potentially pointing toward personalized diabetes prevention or treatment strategies.
What could go wrong
This is an early-stage exploratory study, so findings may not directly translate into treatments. The clamp and biopsies are invasive and carry some risk.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

About 100 people

The number the study aims to enrol. It can still change while the study runs.

Expected to start

Aug 2026

An estimate. Start dates often move.

Expected to finish

Jul 2031

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 to 75 years

Sex

Anyone

Healthy volunteers

Accepted

You do not need to have the condition being studied to take part.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Males and Females Age 18-75 * Body Mass Index (BMI) \> 18 * Normal glucose tolerance as defined by: Fasting blood sugar \< 100 mg/dL 2-hour Oral Glucose Tolerance Test (OGTT) \< 140mg/dL Stable weight over the past 3 months defined as \>±5% change in body weight * Hemoglobin A1c \< 5.7 * Creatinine \< 2 * Aspartate aminotransferase/Alanine transaminase (AST/ALT) \< 75 * Blood sodium 135 to 145 mEq/L * Blood potassium 3.6 to 5.2 mmol/L\[MH1.1\] Exclusion Criteria: * Urine albumin excretion\>300mg/day * Partial thromboplastin time (PTT) \>35International normalized ratio (INR) \> 1.2 * No oral corticosteroids for 1 month * No Sodium-glucose co-transporter 2 (SGLT2) inhibitor for 3 months * No glucagon-like peptide-1 (GLP-1) receptor agonist for 6 months * Any anti-platelet or anti-coagulation medication other than as needed for Pain Management * No alcohol 4 days before the insulin clamp and biopsy procedure * No acute structural knee injuries * No Rheumatologic muscular or nervous system disease * Pregnancy, Intentions to become pregnant, or Breastfeeding * Blood Pressure \>170/110 * Temperature \> 100F * Triglycerides \> 400 by lipid panel * Hemoglobin \<10g/dL * 1+ or greater Blood on Urinalysis * 2+ or greater Protein on Urinalysis * Electrocardiogram (EKG) abnormalities, including but not limited to ST elevations, T wave abnormalities, evidence of recent prior infarct

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Insulin stimulated are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

Insulin Resistance

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Insulin stimulated

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    1 site. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • Texas Diabetes Institute - University Health System, San Antonio, Texas 78207

    RECRUITING

    San Antonio, Texas, 78229, United States